# EDGAR Filing Document

**Accession Number:** 0001553846
**File Stem:** 0001178913-26-001275
**Filing Date:** 2026-3
**Character Count:** 6551
**Document Hash:** 6031f39591edad23e56317427a5ea8be
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-26-001275.hdr.sgml**: 20260318

**ACCESSION NUMBER**: 0001178913-26-001275

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260318

**FILED AS OF DATE**: 20260318

**DATE AS OF CHANGE**: 20260318

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Frish Adi
- **CENTRAL INDEX KEY:** 0002113141

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35773
- **FILM NUMBER:** 26767576

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** C/O REDHILL BIOPHARMA LTD.
- **STREET 2:** 21 HA'ARBA'A STREET
- **CITY:** TEL AVIV
- **PROVINCE COUNTRY:** L3
- **ZIP:** 6473921
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RedHill Biopharma Ltd.
- **CENTRAL INDEX KEY:** 0001553846
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3

**BUSINESS ADDRESS:**
- **STREET 1:** 21 HA'ARBA'A STREET
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 64739
- **BUSINESS PHONE:** 972-3-541-3131

**MAIL ADDRESS:**
- **STREET 1:** 21 HA'ARBA'A STREET
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 64739

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Frish Adi<br><sub>(Last) (First) (Middle)</sub><br>21 HA'ARBA'A STREET<br><sub>(Street)</sub><br>TEL AVIV, ISRAEL 6473921<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>RedHill Biopharma Ltd. [ RDHL ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-18 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Corp & BD Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 276810000<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| American Depositary Shares | <sup>(2)</sup> | <sup>(2)</sup> | Ordinary Shares | 62800000 | <sup>(2)</sup> | D |  |
| Stock Option (Right to Buy) | <sup>(3)</sup> | <sup>(3)</sup> | Ordinary Shares | 250000 | <sup>(3)</sup> | D |  |
| Stock Option (Right to Buy) | <sup>(4)</sup> | <sup>(4)</sup> | Ordinary Shares | 370000 | <sup>(4)</sup> | D |  |
| Stock Option (Right to Buy) | <sup>(5)</sup> | <sup>(5)</sup> | Ordinary Shares | 600000 | <sup>(5)</sup> | D |  |
| Stock Option (Right to Buy) | <sup>(6)</sup> | <sup>(6)</sup> | Ordinary Shares | 750000 | <sup>(6)</sup> | D |  |

---

### Footnotes:

(1) Represents 27,681 unvested restricted share units ("RSUs"), each with respect to one American Depositary Share ("ADS"), which represents 10,000 ordinary shares, par value NIS 0.01 per share ("Ordinary Shares"), of RedHill Biopharma Inc. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares.

(2) Represents 6,280 ADSs, which are convertible at any time, at the holder's election and have no expiration date.

(3) Represents stock option to purchase 250,000 Ordinary Shares (equivalent to 25 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $5,000 per ADS and the option expires on March 21,2028.

(4) Represents stock option to purchase 370,000 Ordinary Shares (equivalent to 37 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $5,000 per ADS and the option expires on May 6, 2029.

(5) Represents stock option to purchase 600,000 Ordinary Shares (equivalent to 60 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $4,870 per ADS and the option expires on March 25, 2030.

(6) Represents stock option to purchase 750,000 Ordinary Shares (equivalent to 75 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $7,080 per ADS and the option expires on April 28, 2031.

**Signature:** /s/ Adi Frish  
**Date:** 2026-03-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**